Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 8/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24739420 | 0.88 | HRH3 (0.47) | ABHD6POLBSRCGHSR | |
| SCHEMBL24739545 | 0.88 | POLB (0.42) | POLBSRCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12021295 | 0.88 | SRC (0.48) | SRCMEN1KMT2AUSP30 | |
| SCHEMBL2434824 | 0.88 | SRC (0.48) | SRCMEN1KMT2AUSP30 | |
| SCHEMBL2431924 | 0.85 | MEN1 (0.44) | SRCMEN1KMT2A | |
| SCHEMBL5156895 | 0.85 | MEN1 (0.44) | SRCMEN1KMT2A | |
| SCHEMBL3863158 | 0.85 | GRIN1 (0.43) | ABHD6GRIN1GRIN2BGHSRSLC6A2 | |
| SCHEMBL17794123 | 0.85 | SLC6A2 (0.45) | POLBSRCGHSRSLC6A2SLC6A4 | |
| SCHEMBL24739053 | 0.83 | GPR119 (0.44) | GRIN1GRIN2BPOLBSRC | |
| SCHEMBL3862645 | 0.83 | P2RX3 (0.47) | ABHD6POLBGHSRSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585885-B2 | Pyrrolidine derivatives useful as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | ELI LILLY AND COMPANY | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | BACE1, BACE2, PSEN1 | ABHD6 3265/4885GRIN1 53/4885GRIN2B 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.